Humacyte
HUMA
28 hedge funds and large institutions have $30.9M invested in Humacyte in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 9 closing their positions.
92% more capital inflows, than outflows
Capital inflows: $13.1M | Capital outflows: $6.83M
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
22% more funds holding
Funds holding: 23 → 28 (+5)
5.94% more ownership
Funds ownership: 23.31% → 29.25% (+5.9%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$2.83M |
| 2 |
Cowen and Company
New York
|
+$2.48M |
| 3 |
P. Schoenfeld Asset Management (PSAM)
New York
|
+$2.06M |
| 4 |
Arena Capital Advisors
Los Angeles,
California
|
+$1.03M |
| 5 |
Tenor Capital Management
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
-$3.21M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.45M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$494K |
| 4 |
NM
Newtyn Management
New York
|
-$437K |
| 5 |
Eversept Partners
New York
|
-$350K |
HUMA Hedge Fund Activity: Q2 2021 in Review
28 of the 5,770 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q2 2021, worth a combined $30.9M — up 18% from $26.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new HUMA positions and 9 closed out — a net gain of 5 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $2.83M. The largest seller was Alpine Global Management, cutting an estimated $3.21M.
- 28 institutional investors held Humacyte (HUMA) as of Q2 2021, up from 23 in Q1 2021.
- Funds reported $30.9M of Humacyte stock for Q2 2021, up 18% quarter-over-quarter.
- 14 funds opened new Humacyte positions in Q2 2021 and 9 closed out, a net change of +5 holders.
- The largest Humacyte buyer in Q2 2021 was Altium Capital Management, an estimated $2.83M added.
- The largest Humacyte seller in Q2 2021 was Alpine Global Management, an estimated $3.21M sold.
Based on aggregated 13F filings for Q2 2021.